Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vion (formerly Oncorx) interesting play on Gene Therapy -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (134)	4/12/1999 11:10:00 AM
From: Volsi Mimir	Read Replies (1) \| Respond to of 370

Vion Demonstrates Readiness of First Tumor-Targeting Salmonella for Human Testing Against Solid Tumors Stability, Safety and Efficacy Demonstrated for Novel Bacterial Anticancer Agent biz.yahoo.com NEW HAVEN, Conn., April 12 /PRNewswire/ -- Research by scientists at Vion Pharmaceuticals (Nasdaq: VION - news) and their Yale University collaborators demonstrates the suitability of the company's lead TAPET® vector, VNP20009, to enter human clinical testing. At the annual meeting of the American Association of Cancer Research (AACR) Vion scientists presented data demonstrating the genetically engineered Salmonella bacteria's overall safety profile and tumor targeting ability, including TAPET's safety when administered to non-human primates. In addition, they reported the ability of unarmed TAPET organisms (without ''warheads'') to inhibit both primary and metastatic tumors by more than 90% and to prolong survival in mouse xenograft models (human tumor tissue transplanted into mice) of several human cancers. In March, Vion announced that the company had filed an Investigational New Drug (IND) application to begin human safety testing with TAPET in the United States later this year. The U.S. filing is in addition to regulatory filings made by Vion in support of clinical trials of TAPET in Europe. Vion is developing TAPET organisms as vectors for the targeted, systemic delivery of anticancer agents to tumors throughout the body.

To: Jim Oravetz who wrote (134)	4/16/1999 12:59:00 PM
From: Jim Oravetz	Read Replies (2) \| Respond to of 370

Vion Pharma Gets $3.3M In Private Placement 4/15/99 NEW HAVEN, Conn. (Dow Jones)--Vion Pharmaceuticals Inc. (VION) received about $3.3 million from a private placement of 726,306 common shares for about $4.47 a share. In a press release Thursday, the biopharmaceutical company said participants included existing institutional investors Elliott Associates L.P. and Westgate International L.P., as well as new investors United Equities Commodities Co. and Wechsler and Co. The company may sell up to $750,000 more of its common shares. The sale will provide funding for the company, particularly for research and development and corporate purposes, through the year 2000. The company also named Chief Executive Alan Kessman president, replacing John Spears, who a company spokesperson said is leaving to pursue other projects. Nasdaq SmallCap-traded shares of Vion closed Thursday up 1/8, or 2.3%, at 5 1/2 on composite volume of 25,200 shares. Average daily volume is 118,798 shares. Elliott Grp Reports 17.93% Vion Pharmaceutical Stake Dow Jones Newswires 4/16/99 WASHINGTON -- A group including Elliott Associates L.P. reported a 17.93% investment stake in Vion Pharmaceuticals Inc. (VION). In a filing Friday with the Securities and Exchange Commission, the group said it bought 446,957 common shares on April 8 at $4.47 a share, and currently holds 3.01 million shares of the New Haven, Conn., company. I'm wondering about Spears leaving. Kessman ran Executone before retiring and resurfacing at Vion. I'm not sure why he decided to get back into the rat race. He did not work any wonders at Executone. my limited knowledge of them shows that they did not make much money while he was at the helm. Any thoughts on this? Jim